ArticleMikrochimica acta2025
Rapid and facile detection of Mycoplasma pneumoniae 16S rRNA based on CHA-FICA system.
Article in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Research progress on detection technologies for Mycoplasma pneumoniae.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- Establishment and application of a rapid and visual detection method forBiosafety and health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Mycoplasma pneumoniae (MP) is a major a rapid, sensitive and reliable method for the detection of 16S ribosomal RNA (16S rRNA) was developed based on catalytic hairpin assembly (CHA) technology and digoxine-biotin double-labeled fluorescence immunochromatography (FICA) strip. The signal amplification achieved by CHA avoids the dependence on expensive thermal cycling equipment. The method can obtain the results within 1 h in the absence of an enzyme, and the minimum detection limit can reach 1 pM. It has good specificity and can effectively distinguish target sequences from non-target sequences. After verification with adult samples and pediatric samples, it was found that CHA-FICA detection was highly consistent with those of PCR detection, indicating that it has clinical application potential and is expected to be used in clinical screening and treatment detection of mycoplasma pneumoniae (MP) infection.
Indexed as
Identifiers
39893283What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.